Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion.

Cho KH, Jeong BY, Park CG, Lee HY.

Arch Pharm Res. 2019 Jun;42(6):519-530. doi: 10.1007/s12272-019-01149-6. Epub 2019 Apr 19.

PMID:
31004257
2.

Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.

Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB.

Oncogene. 2014 May 29;33(22):2846-56. doi: 10.1038/onc.2013.259. Epub 2013 Jul 15.

3.

Curcumin inhibits LPA-induced invasion by attenuating RhoA/ROCK/MMPs pathway in MCF7 breast cancer cells.

Sun K, Duan X, Cai H, Liu X, Yang Y, Li M, Zhang X, Wang J.

Clin Exp Med. 2016 Feb;16(1):37-47. doi: 10.1007/s10238-015-0336-7. Epub 2015 Jan 18.

PMID:
25596714
4.

EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol.

Jeong KJ, Cho KH, Panupinthu N, Kim H, Kang J, Park CG, Mills GB, Lee HY.

Mol Oncol. 2013 Feb;7(1):121-9. doi: 10.1016/j.molonc.2012.10.001. Epub 2012 Oct 23. Erratum in: Mol Oncol. 2019 Jun;13(6):1462-1464.

5.

Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells.

Castellana B, Aasen T, Moreno-Bueno G, Dunn SE, Ramón y Cajal S.

Oncotarget. 2015 Nov 10;6(35):38239-56. doi: 10.18632/oncotarget.5664.

6.

YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro.

Lim JP, Shyamasundar S, Gunaratne J, Scully OJ, Matsumoto K, Bay BH.

BMC Cancer. 2017 Mar 16;17(1):201. doi: 10.1186/s12885-017-3187-7.

7.

Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.

Gunasekaran VP, Nishi K, Sivakumar D, Sivaraman T, Mathan G.

Eur J Pharm Sci. 2018 Apr 30;116:2-14. doi: 10.1016/j.ejps.2017.09.019. Epub 2017 Sep 12.

PMID:
28916481
8.

The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.

Jeong KJ, Park SY, Cho KH, Sohn JS, Lee J, Kim YK, Kang J, Park CG, Han JW, Lee HY.

Oncogene. 2012 Sep 27;31(39):4279-89. doi: 10.1038/onc.2011.595. Epub 2012 Jan 16. Erratum in: Oncogene. 2019 Jun;38(25):5108-5110.

PMID:
22249252
9.

EZH2-Mediated microRNA-139-5p Regulates Epithelial-Mesenchymal Transition and Lymph Node Metastasis of Pancreatic Cancer.

Ma J, Zhang J, Weng YC, Wang JC.

Mol Cells. 2018 Sep 30;41(9):868-880. doi: 10.14348/molcells.2018.0109. Epub 2018 Sep 18.

10.

Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.

Shao S, Zhao X, Zhang X, Luo M, Zuo X, Huang S, Wang Y, Gu S, Zhao X.

Mol Cancer. 2015 Feb 3;14:28. doi: 10.1186/s12943-015-0295-3.

11.

The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer.

Li Z, Hou P, Fan D, Dong M, Ma M, Li H, Yao R, Li Y, Wang G, Geng P, Mihretab A, Liu D, Zhang Y, Huang B, Lu J.

Cell Death Differ. 2017 Jan;24(1):59-71. doi: 10.1038/cdd.2016.95. Epub 2016 Oct 7.

12.

LncRNA SNHG6 promotes the migration, invasion, and epithelial-mesenchymal transition of colorectal cancer cells by miR-26a/EZH2 axis.

Zhang M, Duan W, Sun W.

Onco Targets Ther. 2019 May 2;12:3349-3360. doi: 10.2147/OTT.S197433. eCollection 2019.

13.
14.

β-Arrestin2 regulates lysophosphatidic acid-induced human breast tumor cell migration and invasion via Rap1 and IQGAP1.

Alemayehu M, Dragan M, Pape C, Siddiqui I, Sacks DB, Di Guglielmo GM, Babwah AV, Bhattacharya M.

PLoS One. 2013;8(2):e56174. doi: 10.1371/journal.pone.0056174. Epub 2013 Feb 6.

15.

The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).

Dutta S, Wang FQ, Wu HS, Mukherjee TJ, Fishman DA.

Gynecol Oncol. 2011 Oct;123(1):129-37. doi: 10.1016/j.ygyno.2011.06.006. Epub 2011 Jul 22.

PMID:
21782227
16.

Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.

Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B.

Int J Gynecol Cancer. 2013 Jul;23(6):997-1005. doi: 10.1097/IGC.0b013e318296a265.

17.

VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion.

Wang FQ, Barfield E, Dutta S, Pua T, Fishman DA.

Gynecol Oncol. 2009 Dec;115(3):414-23. doi: 10.1016/j.ygyno.2009.08.019. Epub 2009 Sep 18.

PMID:
19765808
18.

Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells.

Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M, Suh DS, Yoon MS, Chang CL, Jung JS, Kim JH.

Stem Cells. 2008 Mar;26(3):789-97. Epub 2007 Dec 6.

19.

EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Moore HM, Gonzalez ME, Toy KA, Cimino-Mathews A, Argani P, Kleer CG.

Breast Cancer Res Treat. 2013 Apr;138(3):741-52. doi: 10.1007/s10549-013-2498-x. Epub 2013 Mar 29.

20.

The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer.

Sahay D, Leblanc R, Grunewald TG, Ambatipudi S, Ribeiro J, Clézardin P, Peyruchaud O.

Oncotarget. 2015 Aug 21;6(24):20604-20.

Supplemental Content

Support Center